Back to top
more

Ohr Pharmaceuticals, Inc. (OHRP)

(Delayed Data from NSDQ)

$2.65 USD

2.65
460,845

+0.05 (1.92%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.69 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

NeuBase Therapeutics, Inc. [OHRP]

Reports for Purchase

Showing records 1 - 20 ( 43 total )

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 1

08/16/2018

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 2

07/03/2018

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for OHRP

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 3

01/05/2018

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 4

01/05/2018

Company Report

Pages: 6

MAKO Results Come Out Negative; Downgrade to Neutral

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 5

12/28/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 6

12/27/2017

Company Report

Pages: 7

Treat Yourself Before MAKO Results in January; Affirm Buy

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 7

12/19/2017

Company Report

Pages: 8

Docs Are Bullish on the Success of MAKO Trial; Affirm Buy

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 8

12/19/2017

Daily Note

Pages: 3

Cleantech - Industrial Growth

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 9

12/15/2017

Company Report

Pages: 7

OHRP YE17 Recap: Squalamine at the Finish Line While Others Dropped like Flies

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 10

12/08/2017

Industry Report

Pages: 5

Healthcare -Will Squalamine Work For Wet-AMD In Upcoming MAKO Study Readout in Jan.?

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 11

11/29/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 12

11/28/2017

Company Report

Pages: 7

Squalamine Remains Strong Wet-AMD Combo Player; Affirm Buy

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 13

11/27/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 14

11/27/2017

Company Report

Pages: 25

Squalamine, There Is More than Meets the Eye; Initiating with Buy

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 75.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 15

10/06/2017

Company Report

Pages: 3

We are terminating coverage due to the departure from the firm of the covering analyst

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 16

08/16/2017

Company Report

Pages: 6

Riding the MAKO and Expect to Make Landfall in Early 2018

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 25.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 17

02/17/2017

Daily Note

Pages: 3

Ohr Phase 3 Condensed to Provide Data Sooner

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 18

12/23/2016

Company Report

Pages: 8

Squala-be-mine

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 25.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 19

12/19/2016

Company Report

Pages: 4

We are dropping coverage due to the departure of the covering analyst.

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: NeuBase Therapeutics, Inc.

Industry: Medical - Drugs

Record: 20

12/13/2016

Company Report

Pages: 4

What Fovista''s Downfall Means for Ohr: Lesion Characteristics and Size Matters

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party
// eof